Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT02700087 Withdrawn - Laryngomalacia Clinical Trials

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

Start date: February 2016
Phase: N/A
Study type: Interventional

All neonates, ages 0 to 4 months, presenting to LPCH pediatric ENT clinic for airway difficulties or stridor will be screened for inclusion. As is consistent with an acceptable standard of medical care, these children will undergo a flexible nasal endoscopic exam to make the diagnosis of laryngomalacia, as well as be weighed and a breastfeeding history taken. If laryngomalacia is present, the study staff with then administer the Infant Gastroesophageal Reflux Questionnaire (IGERQ) and an airway symptoms questionnaire (ASQ). Those babies with an IGERQ score of less than sixteen (no more than mild reflux) and an ASQ score greater than six will be eligible for randomization. The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily). Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo. A secondary outcome will be weight gain in percentile. If the patient's I-GERQ score goes above 16 at any time in the study, the patient will be crossed over to the treatment arm and started on medical treatment.

NCT ID: NCT02699060 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD

Start date: February 2016
Phase: N/A
Study type: Interventional

This study is proposed to evaluate the role of motoric dysfunctions and type of refluxate in GERD patients, analyzed the blood monocyte/macrophage phenotypes of gastroesophageal reflux diseases (GERD) patients.

NCT ID: NCT02689999 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Start date: February 2016
Phase: Phase 4
Study type: Interventional

It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.

NCT ID: NCT02685436 Completed - Clinical trials for Gastroesophageal Reflux Disease

Role of Pepsin Assay in Wheezy Infants

Start date: March 2013
Phase: Phase 4
Study type: Interventional

Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden macrophage index and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole then re-evaluated for symptoms control and exacerbations recurrence.

NCT ID: NCT02685150 Completed - Clinical trials for Gastroesophageal Reflux Disease

Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease

Start date: January 2016
Phase: N/A
Study type: Interventional

Endoscopic Tri-Modal Imaging which combines Narrow-band Imaging(NBI), Autofluorescence Imaging (AFI) and White-light Imaging (WLI) could be used to identify the indistinct changes in the gut caused by reflux disease,either acid reflux or bile reflux, which make it possible to differentiate reflux disease from functional dyspepsia (FD).

NCT ID: NCT02670642 Completed - Clinical trials for Gastroesophageal Reflux

Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

NEED
Start date: August 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare on demand with continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD), with esomeprazole 20-mg once daily, with regards to willingness to continue in the study as a result of satisfactory treatment over a six-month long term management period, after initial symptom relief.

NCT ID: NCT02637557 Completed - Clinical trials for Gastroesophageal Reflux Disease

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Start date: March 1, 2016
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

NCT ID: NCT02629081 Completed - GERD Clinical Trials

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

Start date: March 2015
Phase: N/A
Study type: Observational

When treating persistent heartburn from gastroesophageal reflux disease (GERD) that does not respond to conventional treatment (a class of medications called proton pump inhibitors), it is important to be able to distinguish between erosive GERD and non-erosive GERD (called NERD). Currently the best method the investigators have to make this distinction is esophageal 24-hour pH and impedance testing. The test involves inserting a catheter into the esophagus through the nose and having the catheter maintained in this position for 24 hours This test is invasive, can be uncomfortable, and it is expensive and time consuming. The investigators are hoping that image enhanced technology will identify characteristics that are found more commonly in patients with non-erosive GERD compared to controls and therefore provide evidence that may allow us to replace pH and impedance testing with the image enhanced endoscopy as the best way to diagnose NERD. Participants will be either patients undergoing an upper endoscopy as part of their standard clinical evaluation for heartburn that does not respond to PPIs or patients undergoing standard clinical evaluation endoscopy for other reasons.

NCT ID: NCT02625077 Withdrawn - Clinical trials for Gastroesophageal Reflux

Valvuloplasty as Alternative to Toupet Fundoplication for GERD

VANTAGE
Start date: January 2016
Phase: N/A
Study type: Interventional

This monocenter randomized controlled trial aims to compare postoperative outcomes of a laparoscopic valvuloplasty with a Toupet fundoplication in patients with GERD with a maximum hiatal hernia of 3cm. In addition, an economic evaluation of the new intervention will be done in order to determine cost-effectiveness and costs per quality-adjusted life-year (QALY).

NCT ID: NCT02623062 Completed - Clinical trials for Gastro-esophageal Reflux Disease (GERD)

Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

Start date: December 2013
Phase: Phase 3
Study type: Interventional

This study is being conducted in China to provide evidence for inclusion in applications to competent authorities that the Compound Sodium Alginate Oral Suspension sachet is effective in managing the symptoms of heartburn and acid regurgitation in patients with gastro-esophageal reflux disease (GERD).